Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
Earnings Data
Report Date
Nov 05, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.05Last Year’s EPS
1.37Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Emergent, with significant financial improvements, increased guidance, and strong performance in international sales and NARCAN revenue. However, there were some declines in specific product sales and a decrease in revenue compared to the first half of 2024, which are being managed through strategic initiatives.Company Guidance
Revenue and EBITDA Performance
Second quarter revenues reached $141 million, surpassing the guidance range of $95 million to $120 million by $21 million. Year-to-date adjusted EBITDA is $106 million, leading to an increased guidance range of $175 million to $200 million for 2025.
Financial Improvements
Liquidity has increased by $297 million year-to-date, with a current total financial capacity of $367 million. Net leverage has improved significantly to 1.9x debt-to-adjusted EBITDA from 9.9x in the second quarter of 2024.
International Sales and MCM Performance
International medical countermeasure (MCM) sales represent 40% of year-to-date revenues, and smallpox revenue saw material year-over-year improvement with a significant increase in international demand.
NARCAN Revenue Growth
NARCAN sales rebounded by 50% since the first quarter of 2025, following one-time events, and have gained market visibility, including participation in Amazon Prime Day and integration into Humana Medicare Part D.
Share Repurchase Program
A 12-month share repurchase program of $50 million has been implemented, with 1.1 million shares repurchased in the second quarter.
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $6.03 | $8.24 | +36.65% |
May 07, 2025 | $4.74 | $6.36 | +34.18% |
Mar 03, 2025 | $6.83 | $6.39 | -6.44% |
Nov 06, 2024 | $9.20 | $11.00 | +19.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at Nov 05, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2025 (Q3) is 0.05.